Actively Recruiting
Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)
Led by MEDICOVER SP Z O.O. · Updated on 2025-11-20
220
Participants Needed
9
Research Sites
303 weeks
Total Duration
On this page
Sponsors
M
MEDICOVER SP Z O.O.
Lead Sponsor
N
National Institute of Cardiology, Warsaw, Poland
Collaborating Sponsor
AI-Summary
What this Trial Is About
The EPISODE VT trial is designed to compare efficacy and safety of two modalities for interventional treatment - endocardial ablation and endo-epicardial ablation in a population of patients with post myocardial infarction (ICD 10 - I25.2) ventricular tachycardias (ICD 10 - I47.2), who are protected by an implantable cardioverter-defibrilator (ICD) and meet study inclusion criteria.
CONDITIONS
Official Title
Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Status after myocardial infarction at least 3 months before joining the study
- Documented ventricular tachycardia or ventricular fibrillation after myocardial infarction
- Implantable cardioverter-defibrillator (ICD) implanted at least 2 weeks before ablation, or CRT-D implanted at least 2 months before ablation
- History of one or more of the following: high energy ICD intervention, three or more antitachycardia pacing therapies including one symptomatic, electrical storm (three or more VT episodes in 24 hours), or sustained VT recorded on ECG
- Age between 18 and 85 years
- Signed informed consent to participate in the study
You will not qualify if you...
- Obesity with body mass index (BMI) greater than 40 kg/m2
- Left ventricle ejection fraction less than 20%
- Pregnancy or breastfeeding
- Renal failure with estimated glomerular filtration rate (eGFR) less than 20 mL/min/1.73m2
- Fresh blood clot in the left ventricle
- Suspected massive adhesions in the pericardium that could hinder pericardial puncture
- Previous ablation for post-infarction ventricular tachycardia in the left ventricle
- History of heart surgery
- Acute conditions preventing ablation, including active infection or overt hyperthyroidism
- Active cancer
- Heart failure classified as NYHA class IV
- Life expectancy less than 12 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Medicover Hospital
Warsaw, Masovian Voivodeship, Poland, 02-972
Actively Recruiting
2
Medical University of Warsaw
Warsaw, Masovian Voivodeship, Poland
Actively Recruiting
3
National Institute of Cardiology
Warsaw, Masovian Voivodeship, Poland
Not Yet Recruiting
4
University Hospital No. 1 in Bydgoszcz
Bydgoszcz, Poland
Not Yet Recruiting
5
University Clinical Center based in Gdańsk
Gdansk, Poland
Not Yet Recruiting
6
Independent Public Health Care Facility University Hospital in Krakow
Krakow, Poland
Not Yet Recruiting
7
University Clinical Hospital in Poznań
Poznan, Poland
Not Yet Recruiting
8
University Clinical Hospital No. 2 PUM in Szczecin
Szczecin, Poland
Not Yet Recruiting
9
Grochowski Hospital named after Dr. Rafał Masztak, MD
Warsaw, Poland
Not Yet Recruiting
Research Team
D
Derejko P Prof. Paweł Derejko, MD, PhD
CONTACT
F
Fabijańska M Project Manager for Clinical Trials in Medicover Hospital
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here